Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics is still in a transitional phase, but with strong management and a growing demand for their non-surgical, non-invasive, and low-cost solution for sleep-disordered breathing, the company has potential to capitalize on the sleep center opportunity and achieve profitability in the near future. While there are risks such as low visibility on revenues and margins, as well as potential share dilution, the company's multi-billion-dollar market potential and favorable product positioning make it an attractive investment opportunity with a BUY rating and a 12-month price target of $3.00, representing 2x upside from the current share price.

Vivos Therapeutics is facing several challenges that contribute to the negative outlook. This includes a sharp increase in expenses due to merger consolidation, the need for more financing to sustain operations, and risks in achieving its price target due to potential competition and inability to secure capital. Additionally, the current standard of care for sleep-disordered breathing involves consistent use of CPAP devices, making compliance rates low. Vivos' alternative treatment option, although promising, has its own challenges and may take years to become the first-line option. Overall, these factors suggest that Vivos Therapeutics may struggle to achieve sustained profitability and may face difficulties in penetrating the market.